Cell and gene therapy landscape assessment
Global development landscape assessment of multiple ATMPs to support commercial decision making

This project utilised the API platform
Scope:
Global
Therapy Area:
Orphan disease
Client:
Global pharmaceutical company
The Challenge
The client required an evaluation of pipeline products for an orphan disease to inform planning and investment decisions
Project objectives
To guide the client team through the identification and evaluation of ATMPs in development for rare ophthalmology indications, including landscape analysis, recommendations of ‘ones to watch’, commercial forecasting and strategic evaluation for priority assets
Approach
Secondary research of the clinical landscape and pipeline analysis, followed by a KOL and payer primary research programme to validate the clinical opportunity and pricing & market access potential for priority assets. A commercial forecast was developed, and priority assets were scored using primary research outputs
VALUE DELIVERED
An evidence-based evaluation of the global development landscape was delivered including a SWOT analysis and a commercial forecast model projecting revenue potential and market share for each priority asset